



DHL Agrees to Acquire SDS Rx Expanding Its Life Sciences and Healthcare Capabilities

- Acquisition will add long-term care and specialty pharmacies, radiopharmacies, and health system networks to DHL Supply Chain's life sciences and healthcare customer base
- Strengthens DHL's ability to deliver integrated, end-to-end solutions across the full life sciences and healthcare value chain through the final mile
- Acquisition will mark second healthcare purchase for DHL in 2025

Bonn, September 9, 2025: DHL Supply Chain, the world's leading contract logistics provider, is strengthening its life sciences and healthcare (LSHC) capabilities by agreeing to acquire SDS Rx, a provider of final-mile delivery and specialized healthcare transportation for long-term care and specialty pharmacies, radiopharmacies and health system networks.

The strategic acquisition will further expand DHL's healthcare logistics portfolio under DHL Health Logistics, enhancing the company's ability to deliver integrated, time-critical solutions across every stage of the LSHC supply chain.

Processing specialized healthcare deliveries from more than 200 locations across the U.S., SDS Rx will add final-mile logistics services to DHL's healthcare transportation network. The acquisition also expands DHL's same-day and expedited delivery capabilities for life sciences and healthcare customers.

"The life sciences and healthcare sector is projected to grow at a compound annual growth rate of 11% through 2030. Specialty pharmacy already accounts for approximately 50% of total prescription drug spending in the U.S., and the number of patients served by specialty pharmacies grew by 12% between 2018 and 2022. The increasing demand for specialty pharma and healthcare solutions presents significant opportunities for DHL to leverage its scale, expertise, and commitment to operational excellence. With this acquisition, we are expanding our healthcare logistics capabilities, attracting a new segment of healthcare customers, and reinforcing our position as a trusted partner in building resilient and connected healthcare supply chains," said Mark Kunar, CEO of DHL Supply Chain North America.

Drew Kronick, Founder, CEO & Managing Partner of SDS Rx stated, "Our mission is to enhance the quality of patient care with every delivery. As the demand for last mile delivery in healthcare continues



to grow, we understand the importance of aligning with a partner who shares our patient-first commitment. Partnering with DHL represents a meaningful step forward, combining our strengths to improve the precision, reliability, and speed of delivery to patients most in need.”

This will be the second healthcare acquisition for DHL Supply Chain in 2025, following its purchase of CryoPDP, a leading specialty courier focused on clinical trials, biopharmaceuticals as well as cell and gene therapies, earlier this year. Together, these acquisitions mark a significant milestone for DHL Group and its strategic growth agenda under Strategy 2030, particularly in expanding its logistics offerings in the Life Sciences and Healthcare sector. They strengthen DHL’s capabilities across critical areas of the healthcare supply chain - from pharmaceuticals and consumer health to animal health and medical technology - all under the umbrella of DHL Health Logistics. With enhanced expertise in cold chain management and specialty pharma logistics, DHL will be even better positioned to meet the complex needs of the healthcare industry and support further targeted growth.

“This acquisition is a meaningful step in expanding our ability to serve patients with precision and care. By integrating SDS Rx’s specialized final-mile capabilities into our operations, we are extending our reach into critical healthcare segments, scaling our Pharma Specialized Network and further strengthening our global DHL Health Logistics . It reinforces our commitment to delivering reliable, patient-centric solutions across the entire life sciences and healthcare supply chain.” said Hendrik Venter, Global CEO of DHL Supply Chain.

DHL Supply Chain is committed to ensuring a seamless transition for customers and associates, with all employees becoming part of the DHL Supply Chain family. SDS Rx operations will be integrated into DHL Supply Chain North America’s Life Science & Healthcare business, and all teams will continue to operate under local leadership.

The closing of the acquisition is subject to regulatory approvals.

1. *Specialty Pharmacy Statistics: Market Data Report 2025*

– End –

Media Contact:

DHL Group

Press release



Media Relations

Daniel Pohl

Phone: +49 228 182-9944

E-mail: pressestelle@dhl.com

On the internet: group.dhl.com/press

Follow us at: twitter.com/DHLglobal

DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 400,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of DHL Group. The Group generated revenues of approximately 84.2 billion euros in 2024. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.